SG Americas Securities LLC Has $7.89 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

SG Americas Securities LLC increased its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 5.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 113,673 shares of the company's stock after buying an additional 5,948 shares during the quarter. SG Americas Securities LLC's holdings in Novo Nordisk A/S were worth $7,893,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of NVO. Center for Financial Planning Inc. lifted its position in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after buying an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL lifted its position in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the last quarter. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S in the fourth quarter worth $29,000. Transce3nd LLC bought a new stake in Novo Nordisk A/S in the fourth quarter worth $33,000. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in Novo Nordisk A/S in the fourth quarter worth $39,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NVO. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday. BNP Paribas started coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating for the company. Finally, BMO Capital Markets restated a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Trading Down 1.4%

NVO stock traded down $1.15 during midday trading on Friday, reaching $79.90. 7,465,072 shares of the company's stock traded hands, compared to its average volume of 7,042,462. The company has a market capitalization of $358.57 billion, a P/E ratio of 24.29, a PEG ratio of 0.90 and a beta of 0.66. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The business has a 50-day moving average price of $67.30 and a two-hundred day moving average price of $79.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.